226 related articles for article (PubMed ID: 11668217)
1. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6.
Zanger UM; Fischer J; Raimundo S; Stüven T; Evert BO; Schwab M; Eichelbaum M
Pharmacogenetics; 2001 Oct; 11(7):573-85. PubMed ID: 11668217
[TBL] [Abstract][Full Text] [Related]
2. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
Zhou SF
Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?
Løvlie R; Daly AK; Matre GE; Molven A; Steen VM
Pharmacogenetics; 2001 Feb; 11(1):45-55. PubMed ID: 11207030
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.
Zanger UM; Raimundo S; Eichelbaum M
Naunyn Schmiedebergs Arch Pharmacol; 2004 Jan; 369(1):23-37. PubMed ID: 14618296
[TBL] [Abstract][Full Text] [Related]
5. Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms.
Yu A; Kneller BM; Rettie AE; Haining RL
J Pharmacol Exp Ther; 2002 Dec; 303(3):1291-300. PubMed ID: 12438554
[TBL] [Abstract][Full Text] [Related]
6. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.
Fux R; Mörike K; Pröhmer AM; Delabar U; Schwab M; Schaeffeler E; Lorenz G; Gleiter CH; Eichelbaum M; Kivistö KT
Clin Pharmacol Ther; 2005 Oct; 78(4):378-87. PubMed ID: 16198657
[TBL] [Abstract][Full Text] [Related]
7. CYP2D6 -1584C>G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers.
Llerena A; Dorado P; Ramírez R; Calzadilla LR; Peñas-Lledó E; Álvarez M; Naranjo ME; González I; Pérez B;
Pharmacogenomics; 2013 Dec; 14(16):1973-7. PubMed ID: 24279852
[TBL] [Abstract][Full Text] [Related]
8. Functional properties of CYP2D6 1 (wild-type) and CYP2D6 7 (His324Pro) expressed by recombinant baculovirus in insect cells.
Evert B; Eichelbaum M; Haubruck H; Zanger UM
Naunyn Schmiedebergs Arch Pharmacol; 1997 Mar; 355(3):309-18. PubMed ID: 9089660
[TBL] [Abstract][Full Text] [Related]
9. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
Evans WE; Relling MV
Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
[TBL] [Abstract][Full Text] [Related]
10. Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events.
Toscano C; Klein K; Blievernicht J; Schaeffeler E; Saussele T; Raimundo S; Eichelbaum M; Schwab M; Zanger UM
Pharmacogenet Genomics; 2006 Oct; 16(10):755-66. PubMed ID: 17001295
[TBL] [Abstract][Full Text] [Related]
11. Estimation of the interindividual variability of cytochrome 2D6 activity from urinary metabolic ratios in the literature.
Ito T; Kato M; Chiba K; Okazaki O; Sugiyama Y
Drug Metab Pharmacokinet; 2010; 25(3):243-53. PubMed ID: 20610883
[TBL] [Abstract][Full Text] [Related]
12. A new CYP2D6 allele with a nine base insertion in exon 9 in a Japanese population associated with poor metabolizer phenotype.
Yokoi T; Kosaka Y; Chida M; Chiba K; Nakamura H; Ishizaki T; Kinoshita M; Sato K; Gonzalez FJ; Kamataki T
Pharmacogenetics; 1996 Oct; 6(5):395-401. PubMed ID: 8946471
[TBL] [Abstract][Full Text] [Related]
13. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.
Scordo MG; Spina E; Facciolà G; Avenoso A; Johansson I; Dahl ML
Psychopharmacology (Berl); 1999 Dec; 147(3):300-5. PubMed ID: 10639689
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity.
Neafsey P; Ginsberg G; Hattis D; Sonawane B
J Toxicol Environ Health B Crit Rev; 2009; 12(5-6):334-61. PubMed ID: 20183526
[TBL] [Abstract][Full Text] [Related]
15. Detection of CYP2D6*3 and 2D6*4 allelic variants by PCR-restriction fragment length polymorphism.
Topić E; Stefanović M; Nikolić V; Zoricić I; Ivanisević AM; Zuntar I
Clin Chem Lab Med; 1998 Aug; 36(8):655-8. PubMed ID: 9806480
[TBL] [Abstract][Full Text] [Related]
16. Tramadol-Related Deaths: Genetic Analysis in Relation to Metabolic Ratios.
Aly SM; Tartar O; Sabaouni N; Hennart B; Gaulier JM; Allorge D
J Anal Toxicol; 2022 Aug; 46(7):791-796. PubMed ID: 34480795
[TBL] [Abstract][Full Text] [Related]
17. Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics.
Shen HW; Wu C; Jiang XL; Yu AM
Biochem Pharmacol; 2010 Jul; 80(1):122-8. PubMed ID: 20206139
[TBL] [Abstract][Full Text] [Related]
18. Relevance of CYP2D6 -1584C>G polymorphism for thioridazine:mesoridazine plasma concentration ratio in psychiatric patients.
Dorado P; Peñas-LLedó EM; de la Rubia A; LLerena A
Pharmacogenomics; 2009 Jul; 10(7):1083-9. PubMed ID: 19604081
[TBL] [Abstract][Full Text] [Related]
19. Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17.
Shen H; He MM; Liu H; Wrighton SA; Wang L; Guo B; Li C
Drug Metab Dispos; 2007 Aug; 35(8):1292-300. PubMed ID: 17470523
[TBL] [Abstract][Full Text] [Related]
20. Association between cytochrome P450 2D6 polymorphisms and body fluid methamphetamine concentrations in Japanese forensic autopsy cases.
Matsusue A; Ikeda T; Tani N; Waters B; Hara K; Kashiwagi M; Takayama M; Ikematsu N; Kubo SI; Ishikawa T
Forensic Sci Int; 2018 Aug; 289():33-39. PubMed ID: 29843110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
